title: Antiarthritic effect of lonicerin on Candida albicans arthritis in mice.
abstract: Fungal arthritis is a potentially serious disease resulting in rapid destruction of the joint. Among the various Candida species, Candida albicans is the most commonly associated with fungal arthritis. In the present study, we examined the effect of lonicerin, a flavonoid isolated from Lonicerae Flos, on an arthritis caused by C. albicans cell wall (CACW) in mice. To examine the effect, an emulsified mixture of CACW and complete Freund's adjuvant (CACW/CFA) was injected into BALB/c mice via hind footpad route on days -3, -2, and -1. On Day 0, mice with the swollen footpad received lonicerin at 1 or 2 mg/dose/time intraperitoneally 3 times every other day. The footpad-swelling was measured for 20 days. Results showed that the lonicerin treatment reduced the edema at all dose levels, and, furthermore, there was app. 54% edema reduction in animals given the 2 mg-dose at the peak (day 10) of septic arthritis (p < 0.05). Since the peak, the edema was reduced in similar rates. This antiarthritic activity appeared to be mediated by lonicerin's ability to suppress T cell proliferation, nitric oxide production from macrophages, and shift of cellular immunity from Th1- toward Th2-type responses, all of which are beneficial to treat arthritis. In addition, the flavonoid had anticandidal activity (p < 0.01). These data suggest that lonicerin alone, which has both anti-arthritic and antifungal activities, can result in a combination therapy for the treatment of fungal arthritis due to C. albicans infection.
authors.affiliation: Department of ImmunoMicrobiology, College of Pharmacy, Dongduk Women's University, 23-1 Wolgok-Dong, Sungbuk-Gu, Seoul 136-714, Korea.
authors.forename: Jue-Hee
authors.initials: JH
authors.lastname: Lee
authors.forename: Yongmoon
authors.initials: Y
authors.lastname: Han
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000302:isolation & purification / Q000494:pharmacology / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000008:administration & dosage / Q000302:isolation & purification / Q000494:pharmacology / Q000627:therapeutic use; D000946:Antigens, Fungal / Q000276:immunology*; D001170:Arthritis, Infectious / Q000188:drug therapy* / Q000276:immunology; D002176:Candida albicans / Q000187:drug effects / Q000276:immunology*; D002461:Cell Line, Transformed; D049109:Cell Proliferation / Q000187:drug effects; D002473:Cell Wall / Q000276:immunology*; D002478:Cells, Cultured; D016207:Cytokines / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005260:Female; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000302:isolation & purification / Q000494:pharmacology / Q000627:therapeutic use*; D031239:Lonicera / Q000737:chemistry; D047311:Luteolin / Q000008:administration & dosage / Q000302:isolation & purification / Q000494:pharmacology / Q000627:therapeutic use*; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D009569:Nitric Oxide / Q000378:metabolism; D013601:T-Lymphocytes / Q000187:drug effects / Q000378:metabolism; D058408:Th1-Th2 Balance / Q000187:drug effects
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000935:Antifungal Agents; D000946:Antigens, Fungal; D016207:Cytokines; D007166:Immunosuppressive Agents; C009652:veronicastroside; D009569:Nitric Oxide; D047311:Luteolin